Phase 1 Stomach Cancer Trial, Recruiting NCT05880667 Sponsor: Fox Chase Cancer Center Condition: Stomach Cancer
Back to Stomach Cancer

Phase 1 Stomach Cancer Trial, Recruiting

NCT05880667
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with any type of solid cancer that has spread (metastatic), confirmed through a tissue or cell sample, with at least one tumour in the abdomen or pelvis that has not been treated with radiation, and that can be measured using standard imaging criteria.
  • People who are over 18 years of age.
  • People who are generally well enough to carry out light activity and care for themselves (a doctor will assess this using a standard scale).
  • People whose doctors estimate they are likely to live for at least 12 months.
  • People whose blood test results show that their liver, kidneys, and blood cell counts are within acceptable ranges (the trial site can confirm what specific values are required).
  • People who are able to understand the study and are willing to sign a consent form agreeing to take part.

Who may not be able to join:

  • People who still have significant side effects from a previous cancer treatment at the time of joining (except for mild nerve-related symptoms, hair loss, or fatigue).
  • People who are currently taking part in another clinical trial involving an experimental treatment.
  • People who have cancer that has spread throughout the lining of the abdominal cavity, visible on scans.
  • People who have active tumours visible on scans in parts of the body outside the abdomen or pelvis.
  • People who have six or more active sites of cancer spread in the body.
  • People whose target tumour has previously been treated with radiation therapy.
  • People who have serious uncontrolled health conditions, such as an active infection, uncontrolled heart failure, unstable chest pain, irregular heart rhythm, or a mental health or personal situation that would make it difficult to follow the trial requirements.
  • People who have any condition that their treating doctor determines would make it unsafe to receive the type of radiation treatment used in this trial (confirm with trial site).
  • People who are pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Joshua Meyer, MD, Fox Chase Cancer Center

Phone: 12152141439

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Fox Chase Cancer Center
Registry
ClinicalTrials.gov
Start date
1 August 2023
Est. completion
1 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To assess the ability of adaptive SBRT to deliver increased doses of radiation safely to patients with challenging anatomical locations of metastatic disease without causing unacceptable toxicity.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov